earnings
confidence high
sentiment negative
materiality 0.75
Cogent Biosciences Q1 net loss $72M; cash $245.7M; SUMMIT readout in July
Cogent Biosciences, Inc.
2025-Q1 EPS reported
-$0.52
- Net loss $72.0M vs $58.3M YoY; R&D spend $63.0M (+20% YoY) driven by ongoing trials.
- Cash & securities $245.7M, funded into late 2026; raised $24.3M via ATM in Q1.
- Top-line SUMMIT results in non-AdvSM due July 2025; APEX AdvSM in H2, PEAK GIST by year-end.
- Bezuclastinib OLE data showed 65% mean TSS improvement at 48 weeks; 88% achieved ≥50% reduction.
- Early-stage pipeline (KRAS, PI3Kα, FGFR2/3, ErbB2) preclinical data presented at AACR.